Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Immune checkpoint inhibitors

9 evidence topics · 6 sources

KEYNOTE-057 Cohort A: efficacy in the prescribing information
EndpointPembrolizumab 200 mg every 3 weeks
Participants“n=96”
Complete response rate (95% CI)“41% (31, 51)”
Median duration of response, months (range)“16.2 (0.0+, 30.4+)”
Duration of response ≥12 months, % (n)“46% (18)”
Basis of duration of response“Based on patients (n=39) that achieved a complete response”
KEYNOTE-057 Cohort A: primary publication

“In cohort A of the trial, adults aged 18 years or older with histologically confirmed BCG-unresponsive carcinoma in situ of the bladder, with or without papillary tumours, with an Eastern Cooperative Oncology Group performance status of 0-2, and who were ineligible for or declined radical cystectomy were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The primary endpoint was clinical complete response rate (absence of high-risk non-muscle-invasive bladder cancer or progressive disease), assessed by cystoscopy and urine cytology approximately 3 months after the first dose of study drug.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Median follow-up was 36·4 months (IQR 32·0-40·7).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“39 (41%; 95% CI 30·7-51·1) of 96 patients with BCG-unresponsive carcinoma in situ of the bladder with or without papillary tumours had a complete response at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Grade 3 or 4 treatment-related adverse events occurred in 13 (13%) patients; the most common were arthralgia (in two [2%] patients) and hyponatraemia (in three [3%] patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

KEYNOTE-057 Cohort B: papillary-only disease